Perfect for beginners. Learn how to assess the movement of the ball (semi automatically) to determine the out come of a spin and beat the casino in just a few days. No need to buy a roulette computer. Learn how to beat roulette using real skill. A roulette system that works. AssessBEST is cloud-based and meets the most stringent cyber-secure requirements. AssessBEST was built for and by INDEPENDENT Advisors. AssessBest Advisors determine their carrier “shelf” based on the appointments in place today or tomorrow.

1. Access Better
2. Accessbet Minimum Withdrawal
3. Assess Bet

FansUnite Entertainment Inc (CSE:FANS) (OTCQB:FUNFF) (FRA:4UY) said through its subsidiary Askott Entertainment, it has signed an agreement with Gaming Laboratories International (GLI) to assess the company’s online betting offerings for compliance and certification with GLI-19 Standards for Interactive Gaming Systems and GLI-33 Standards for Event Wagering Systems.

Access Better

The online gaming technology specialist said to complete GLI’s assessment, it will undergo world-class testing procedures for its leading iGaming and sports betting solutions such as the Chameleon Gaming Platform and Askott Entertainment’s suite of random number generator (RNG) games.

READ: FansUnite Entertainment partners with OneComply for US licensing strategy assistance

FansUnite said the GLI-19 and GLI-33 standards certification will allow it to deliver its online gambling products to various US states and provinces in Canada that require gambling firms to be compliant with GLI standards. It added that any additional unique technical requirements that states and provinces may require can be tested by GLI in parallel, which it said will make for the “most efficient certification process” and allow it to enter markets more expeditiously.

“We are pleased to announce that we are on track to complete regulatory procedures to distribute our wagering platforms within the North American market. Our focus is to expand rapidly in the U.S. and Canada, and therefore, we are committed to obtaining favorable assessments from GLI in order to deliver our solutions to an expanded North American gaming market,' FansUnite chief executive Scott Burton said.

Contact the author at calum@proactiveinvestors.com

Follow him on Twitter @Cal_Proac

Accessbet Minimum Withdrawal

Assess Bet

1. Total symptom score (TSS), averaged over the duration of the birch pollen season, in participants who receive a single dose of REGN5713-5714-5715 versus placebo [ Time Frame: Until the end of Birch Pollen Season, up to Week 16 ]
   TSS is a combined score of TOSS and TNSS. TNSS and TOSS are scored as in part 1 each for a combined TSS of 0 (none) to 18 (severe)
   
   
2. Total nasal symptom score (TNSS), averaged over the duration of the birch pollen season, in participants who receive a single dose of REGN5713-5714-5715 versus placebo [ Time Frame: Until the end of Birch Pollen Season, up to Week 16 ]
   Total nasal symptom score (TNSS) is from 0 to 12 and is based on assessment of 4 nasal symptoms graded on a Likert scale ranging from 0 (none) to 3 (severe) for congestion, itching, and rhinorrhea, and from 0 (none) to 3 (5 or more sneezes) for sneezing.
   
   
3. Total ocular symptom score (TOSS), averaged over the duration of the birch pollen season, in participants who receive a single dose of REGN5713-5714-5715 versus placebo [ Time Frame: Until the end of Birch Pollen Season, up to Week 16 ]
   Total ocular symptom score is 0 to 6 and is based on itching/redness/gritty feeling and tearing/watering; each of the 2 symptoms is graded 0 (absent), 1 (mild), 2 (moderate), and 3 (severe)
   
   
4. Daily medication score (DMS), averaged over the duration of the birch pollen season, in participants who receive a single dose of REGN5713-5714-5715 versus placebo [ Time Frame: Until the end of Birch Pollen Season, up to Week 16 ]
   The Daily Medication Score (DMS) is calculated by adding points for each pre-specified medication taken as follows: desloratadine 5 mg 6 points/dose; maximum daily score 6 points, olopatadine 1 mg/mL each drop 1.5 points/drop; maximum daily score 6 points, mometasone furoate 50 ug/dose 2.0 points/spray; maximum daily score 8 points). The scale is 0 (minimum) to 20 (maximum)
   
   
5. Incidence of Treatment-Emergent Adverse Events (TEAEs) throughout the study [ Time Frame: Up to Day 127 ]
   
6. Incidence of Serious TEAEs throughout the study [ Time Frame: Up to Day 127 ]
   
7. Change from baseline to the end of study in birch SPT mean wheal diameter in participants who receive a single dose of REGN5713-5714-5715 versus placebo [ Time Frame: Baseline through Day 127 ]
   
8. Percent change from baseline to the end of study in birch SPT mean wheal diameter in participants who receive a single dose of REGN5713-5714-5715 versus placebo [ Time Frame: Baseline through Day 127 ]
   
9. Serum concentration of REGN5713 over the study duration [ Time Frame: Up to Day 127 ]
   
10. Serum concentration of REGN5714 over the study duration [ Time Frame: Up to Day 127 ]
    
11. Serum concentration of REGN5715 over the study duration [ Time Frame: Up to Day 127 ]
    
12. Incidence of treatment emergent anti-drug antibodies to REGN5713 throughout the study [ Time Frame: Up to Day 127 ]
    
13. Incidence of treatment emergent anti-drug antibodies to REGN5714 throughout the study [ Time Frame: Up to Day 127 ]
    
14. Incidence of treatment emergent anti-drug antibodies to REGN5715 throughout the study [ Time Frame: Up to Day 127 ]
    
15. Number of 'Well Days' [ Time Frame: Until the end of Birch Pollen Season, up to Week 16 ]
    'Well Days' are defined as days when rescue medication is not utilized and the Total symptom score (TSS) is ≤2/18